Stephan Carla, Kalomeris Taylor, Li Yaxin, Kubiak Jeffrey, Racine-Brzostek Sabrina, SahBandar Ivo, Zhao Zhen, Cushing Melissa M, Yang He S
Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10065, USA.
J Clin Med. 2025 Jan 2;14(1):204. doi: 10.3390/jcm14010204.
Creutzfeldt-Jakob disease (CJD) is a rare, fatal, and transmissible neurodegenerative disorder caused by prion proteins. Handling specimens from individuals with suspected or confirmed cases presents a safety challenge to hospital workers including clinical laboratory staff. As no national guidelines exist, the clinical pathology laboratory must establish protocols for handling these specimens to ensure sufficient protective measures. This study aims to explore how various medical institutions manage CJD specimens, as a first step toward developing standardized preanalytical protocols for safe specimen handling by health care professionals. An electronic survey was generated and disseminated to diplomats of the American Board of Clinical Chemistry and was posted on the Listserv platform of the American Society for Microbiology and the Artery forum of the Association for Diagnostics and Laboratory Medicine. The survey evaluated various procedures and precautions implemented, the nature of the specimens processed, and whether they are processed in-house or sent to reference laboratories. A total of 49 responses were collected. Most respondents (64%) noted their laboratories process specimens with a clinical suspicion of CJD regardless of the level of suspicion, 13% handled specimens only if the degree of suspicion was low, and 16% did not process specimens in-house at all. Among those who process CJD specimens, practices varied greatly, including different levels of precautions, use of biological safety cabinets, aliquoting, disposal, and disinfection procedures. A lack of standardization across laboratories exists for the handling of specimens of patients with suspected CJD. This study summarizes the approaches reported by survey respondents, providing a rationale for developing protocols for the safe handling of these specimens and highlighting the need to develop uniform universal standardized processing procedures.
克雅氏病(CJD)是一种由朊病毒蛋白引起的罕见、致命且可传播的神经退行性疾病。处理疑似或确诊病例个体的标本对包括临床实验室工作人员在内的医院工作人员构成安全挑战。由于没有国家指南,临床病理实验室必须制定处理这些标本的方案,以确保采取足够的保护措施。本研究旨在探索各类医疗机构如何管理克雅氏病标本,作为为医疗保健专业人员制定安全标本处理标准化分析前方案的第一步。生成了一份电子调查问卷并分发给美国临床化学委员会的外交官,并发布在美国微生物学会的邮件列表平台以及诊断与实验室医学协会的动脉论坛上。该调查评估了实施的各种程序和预防措施、所处理标本的性质,以及它们是在内部处理还是送往参考实验室。共收集到49份回复。大多数受访者(64%)指出,无论怀疑程度如何,他们的实验室都会处理临床怀疑患有克雅氏病的标本;13%的受访者仅在怀疑程度较低时处理标本;16%的受访者根本不在内部处理标本。在处理克雅氏病标本的受访者中,做法差异很大,包括不同程度的预防措施、生物安全柜的使用、分装、处置和消毒程序。对于疑似克雅氏病患者标本的处理,各实验室缺乏标准化。本研究总结了调查受访者报告的方法,为制定这些标本的安全处理方案提供了依据,并强调了制定统一通用标准化处理程序的必要性。